A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults 18 to 65 years of age
CHC infection as shown on enzyme-linked immunosorbent assay (ELISA) and radioimmunoblot assay (RIBA) or quantifiable hepatitis C virus (HCV) ribonucleic acid (RNA) greater than (\>) 2000 copies per milliliter (copies/mL)
Use of two forms of contraception during study and 6 months after the study in both men and women
Normal renal function (creatinine clearance \[CrCl\] \>80 milliliters per minute \[mL/min\]), moderate renal impairment (CrCl 30 to 50 mL/min), severe renal impairment (CrCl less than \[\<\] 30 mL/min), or ESRD requiring hemodialysis
Patients with ESRD must have been undergoing hemodialysis for at least 2 months
You may not be if
Women who are pregnant or breastfeeding
Male partners of women who are pregnant
Conditions associated with decompensated and/or chronic liver disease
Human immunodeficiency virus (HIV) infection
Interferon or ribavirin treatment within the previous 3 months
Poor hematologic function, including unstable hemoglobin
Significant comorbidity or severe illness which would make the participant unsuitable for the study
Acute renal failure
Clareo Health | A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment
